Ignite Creation Date:
2025-12-24 @ 2:44 PM
Ignite Modification Date:
2025-12-26 @ 6:43 PM
Study NCT ID:
NCT03771859
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2021-09-14
First Post:
2018-12-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
Sponsor:
Bristol-Myers Squibb
Organization:
Study Overview
Official Title:
An Observational Study in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An observational study of melanoma participants who are eligible for and who have initiated treatment with adjuvant nivolumab as part of routine clinical practice.
Detailed Description:
Participants receiving adjuvant nivolumab therapy could be enrolled prospectively and retrospectively.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: